Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 31.71B
March 31, 2026 31.42B
December 31, 2025 31.26B
September 30, 2025 30.96B
June 30, 2025 29.94B
March 31, 2025 29.39B
December 31, 2024 29.35B
September 30, 2024 29.33B
June 30, 2024 28.21B
March 31, 2024 26.99B
December 31, 2023 25.97B
September 30, 2023 24.90B
June 30, 2023 24.02B
March 31, 2023 23.50B
December 31, 2022 22.66B
September 30, 2022 21.44B
June 30, 2022 20.69B
March 31, 2022 19.91B
December 31, 2021 18.77B
September 30, 2021 17.26B
June 30, 2021 15.13B
March 31, 2021 11.98B
December 31, 2020 11.03B
September 30, 2020 10.13B
June 30, 2020 9.057B
Date Value
March 31, 2020 12.13B
December 31, 2019 11.09B
September 30, 2019 10.50B
June 30, 2019 9.756B
March 31, 2019 9.445B
December 31, 2018 8.757B
September 30, 2018 7.868B
June 30, 2018 7.186B
March 31, 2018 6.568B
December 31, 2017 6.144B
September 30, 2017 6.052B
June 30, 2017 5.521B
March 31, 2017 4.866B
December 31, 2016 4.449B
September 30, 2016 4.491B
June 30, 2016 4.077B
March 31, 2016 3.765B
December 31, 2015 3.655B
September 30, 2015 3.297B
June 30, 2015 3.338B
March 31, 2015 2.971B
December 31, 2014 2.542B
September 30, 2014 2.552B
June 30, 2014 2.369B
March 31, 2014 2.211B

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 1.354B
Gilead Sciences, Inc. 11.83B
AbbVie, Inc. -5.935B
Vertex Pharmaceuticals, Inc. 20.25B
Amgen, Inc. 11.69B

Shareholders Equity (Quarterly) Related Metrics